A randomised phase II study of interferon alpha alone or in combination with thalidomide in metastatic renal cancer
Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Adrian L. Harris(University of Oxford), P. Vasey(Wesley Hospital), Poulam M. Patel(Nottingham University Hospitals NHS Trust), David A. Altman(Beatson West of Scotland Cancer Centre), Andrew Protheroe(University of Oxford), Peter J. Selby(Centre for Addiction and Mental Health), K Christodoulos(Cancer Research UK)
Cited by 5
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k